With our Hong Kong Science Park Shenzhen Branch opening since 2023, we have supported over 100 enterprises through our Shenzhen Branch.
Among them, Yicura BioMed completed IIT clinical studies for its world‑first HIV therapeutic vaccine and is collaborating with Shenzhen Third People’s Hospital to advance clinical trials and industrialisation.
Self-Energy Technology has completed five rounds of financing, secured partnerships with domestic industrial leaders such as China Aluminum, and exports its products to Europe, the Americas, the Middle East, and Southeast Asia.
Rafael Biotech signed an agreement with Peking University Shenzhen Hospital to initiate a neurology‑specific clinical study on Alzheimer’s disease, while simultaneously establishing a multi‑centre network with Shenzhen Second People’s Hospital and Zhujiang Hospital of Southern Medical University.
In cross‑boundary cooperation, we partnered with Hangzhou Industrial Investment Group to set up the Hangzhou Innovation Center, which has already brought 15 enterprises to Hong Kong. In 2026, we joined forces with Yuexiu Group to establish a Guangzhou‑Hong Kong platform, further expanding our presence in the Greater Bay Area.